ALK and non-small cell lung carcinoma: The emergence of tyrosine kinase inhibitors (TKIs) targeting ALK rearrangements has demonstrated superior survival benefits compared to conventional chemotherapy, leading to improved prognoses for ALK-positive NSCLC patients (Qin et al., 2024).